

US007521049B2

(12) United States Patent

Wiegand et al.

(54) USE OF VEGF INHIBITORS FOR TREATMENT OF EYE DISORDERS

- (75) Inventors: Stanley J. Wiegand, Croton-on-Hudson, NY (US); Nicholas J. Papadopoulos, LaGrangeville, NY (US); George D. Yancopoulos, Yorktown Heights, NY (US); James P. Fandl, LaGrangeville, NY (US); Thomas J. Daly, New City, NY (US)
- (73) Assignee: Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 11/998,709

(65)

(22) Filed: Nov. 30, 2007

Prior Publication Data

US 2008/0220004 A1 Sep. 11, 2008

Related U.S. Application Data

- (60) Division of application No. 11/218,234, filed on Sep. 1, 2005, now Pat. No. 7,303,747, which is a continuation-in-part of application No. 11/089,803, filed on Mar. 25, 2005, now Pat. No. 7,306,799, which is a continuation-in-part of application No. 10/988,243, filed on Nov. 12, 2004, now Pat. No. 7,303,746, which is a continuation-in-part of application No. 10/009, 852, filed as application No. PCT/US00/14142 on May 23, 2000, now Pat. No. 7,070,959, said application No. 11/218,234 is a continuation-in-part of application No. 11/218,234 is a continuation-in-part of application No. 10/880,021, filed on Jun. 29, 2004, now Pat. No. 7,279, 159, which is a continuation-in-part of application No. 10/609,775, filed on Jun. 30, 2003, now Pat. No. 7,087, 411.
- (60) Provisional application No. 60/138,133, filed on Jun. 8, 1999.
- (51) **Int. Cl.**

DOCKE

A61K 38/18	(2006.01)
C07K 14/71	(2006.01)
C12N 15/62	(2006.01)

(10) Patent No.: US 7,521,049 B2

(45) **Date of Patent:** Apr. 21, 2009

- (52) **U.S. Cl.** **424/134.1**; 424/192.1; 514/2; 514/12; 530/350; 536/23.4
- (58) **Field of Classification Search** None See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,100,071	Α	8/2000	Davis-Smyth et al.
6,897,294	B2	5/2005	Davis-Smyth et al.
2005/0281831	A1	12/2005	Davis-Smyth et al.

FOREIGN PATENT DOCUMENTS

WO	WO97/44453	11/1997
WO	WO98/13071	4/1998
WO	WO99/03996	1/1999

OTHER PUBLICATIONS

Terman, B.I., et al., (1991) Oncogene 6:1677-1683.

Terman, B.I., et al., (1992) Biochem. Biophys. Res. Comm. 187(3):1579-1586.

Davis-Smyth, T., et al., (1996) The EMBO Journal 15(18):4919-4927.

Holash, J., et al., (2002) PNAS 99(17):11393-11398.
Heidaran, M.A., et al., (1990) J. Bio. Chem. 265(31):18741-18744.
Cunningham, S.A., et al., (1997) Biochem. Biophys. Res. Comm. 231:596-599.
Fuh, G., et al., (1998) J. Bio. Chem. 273(18):11197-11204.
Wiesmann, C., et al., (1997) Cell 91:695-704.
Barleon, B., et al., (1997) J. Bio. Chem. 272(16):10382-10388.
Davis-Smyth, T., et al., (1998) J. Bio. Chem. 273(6):3216-3222.

Primary Examiner—Christine J. Saoud Assistant Examiner—Jon M Lockard (74) Attorney, Agent, or Firm—Valeta Gregg, Esq.

(57) ABSTRACT

Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.

15 Claims, 11 Drawing Sheets

Mylan v. Regeneron IPR2021-00880 U.S. Pat. 9,669,069 Exhibit 2035

Find authenticated court documents without watermarks at docketalarm.com.

テcΔC1(a) & VEGFR1R2- FcΔC1(a)	VEGF/VEGFR1R2- FcAC1(a)	0.98	0.94	66.0	0.97 ± 0.02
Binding Stoichiometry of hVEGF165 to Flt1D2Flk1D3. FcAC1(a) & VEGFR1R2- FcAC1(a)	VEGF/Flt1D2FlkD3.FcAC1(a)	0.93	0.97	1	0.96 ± 0.03
Binding Stoichiometr	hVEGF165 (nM)	Ţ	10	50	Average ± StDev


Figure 1

DOCKET

ALARM

Find authenticated court documents without watermarks at docketalarm.com.

Sheet 1 of 11





Α

CKET A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.





Figure 3

Α

Modified Flt Receptor [µg/m] ~KF Find authenticated court documents without watermarks at docketalarm.com.



Find authenticated court documents without watermarks at docketalarm.com.

Α

R

М

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.